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Purpose: Treatment-refractory Giardia cases have increased rapidly within the last decade.
No markers of resistance nor a standardized susceptibility test have been established yet, but
several enzymes and their pathways have been associated with metronidazole (MTZ) resis-
tant Giardia. Very limited data are available regarding genetic variation in these pathways.
We aimed to investigate genetic variation in metabolic pathway genes proposed to be
involved in MTZ resistance in recently acquired, cultured clinical isolates.
Methods: Whole genome sequencing of 12 assemblage A2 and 8 assemblage B isolates was
done, to decipher genomic variation in Giardia. Twenty-nine genes were identified in
a literature search and investigated for their single nucleotide variants (SNVs) in the
coding/non-coding regions of the genes, either as amino acid changing (non-synonymous
SNVs) or non-changing SNVs (synonymous).
Results: In Giardia assemblage B, several genes involved in MTZ activation or oxidative
stress management were found to have higher numbers of non-synonymous SNVs (thior-
edoxin peroxidase, nitroreductase 1, ferredoxin 2, NADH oxidase, nitroreductase 2, alcohol
dehydrogenase, ferredoxin 4 and ferredoxin 1) than the average variation. For Giardia
assemblage A2, the highest genetic variability was found in the ferredoxin 2, ferredoxin 6
and in nicotinamide adenine dinucleotide phosphate (NADPH) oxidoreductase putative
genes. SNVs found in the ferredoxins and nitroreductases were analyzed further by align-
ment and homology modeling. SNVs close to the iron-sulfur cluster binding sites in
nitroreductase-1 and 2 and ferredoxin 2 and 4 could potentially affect protein function.
Flavohemoprotein seems to be a variable-copy gene, due to higher, but variable coverage
compared to other genes investigated.
Conclusion: In clinical Giardia isolates, genetic variability is common in important genes
in the MTZ metabolizing pathway and in the management of oxidative and nitrosative stress
and includes high numbers of non-synonymous SNVs. Some of the identified amino acid
changes could potentially affect the respective proteins important in the MTZ metabolism.
Keywords: drug metabolism, resistance, genetic analysis, metronidazole genes, ferredoxin,
genetic diversity
Introduction
Giardia lamblia is a microaerophilic, eukaryotic and tetraploid parasite, annually
responsible for up to ~280 million human infections worldwide.1 Giardia is endemic
in low- and middle-income countries (LMIC), and infection with the parasite has been
shown to affect growth and cognitive functions in children in resource-poor regions.2,3
In high-income countries, Giardia is usually transmitted by waterborne outbreaks or
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found in returning travelers from LMIC.4,5 Giardiasis is
clinically associated with prolonged diarrhea and stomach
pain, and it may lead to post-infectious sequela, eg, irritable
bowel syndrome and chronic fatigue.6,7
The antibiotic metronidazole (MTZ) is a prodrug belong-
ing to the 5-nitromidazole chemical group, and a common
first-line treatment for giardiasis.8 With its activity against
microaerophilic and anaerobic pathogens, MTZ has
a treatment efficacy of 73–100%.9 MTZ enters the parasite
through passive diffusion, it is activated through enzymatic
reduction and releases toxic intermediates. This reaction can
only occur in an anaerobic or microaerophilic
environment.10,11 Effects of activated MTZ on susceptible
Giardia include protein malfunction, multiplication disrup-
tion, DNA damage and oxidative stress which will lead to
cell death.12–15 MTZ can be activated by four main enzymes
in Giardia: pyruvate-flavodoxin oxidoreductases (PFOR-1
and 2), the thiol-cycling associated enzyme thioredoxin
reductase (TrxR)16 and nitroreductase (NR)-1. The iron-
sulfur (Fe-S) cluster binding proteins, ferredoxins (Fd) have
also been shown to participate in activation of MTZ in
Giardia.16 NR-2, a paralog of NR-1, is hypothesized to
detoxify MTZ by fully reducing the drug without making
toxic intermediates.17–19 While Giardia is exposed to MTZ,
it also has to constantly detoxify oxygen, nitric oxide (NO)
and other harmful chemicals that may affect growth and
viability.20
The majority of proposed resistance mechanisms consist
of either down-regulation of enzymes that render MTZ cyto-
toxic (NR-1, PFORs and TrxR), or up-regulation of enzymes
that can make MTZ an inert molecule (NR-2).19 Most work
regarding drug resistance mechanisms in Giardia has been
done using laboratory induced resistant assemblage A1 iso-
lates, which rarely infects humans, compared to infections
with Giardia assemblage A2 and B, which are common.
MTZ is probably activated through several pathways and
exhibit a pleiotropic mode of action, and resistance to MTZ
has generally taken longer time to develop compared to
resistance against most other antibiotics.21
MTZ resistance in Giardia is a growing problem.
Clinical experience and recent studies of returning trave-
lers have shown that MTZ-refractory Giardia cases have
a prevalence of ~20%.22,23 The prevalence has dramati-
cally increased over the last few years, reaching up to 40%
in a referral outpatient clinic in London.24 The highest
prevalence of MTZ refractory cases have been found in
returning travelers from Asia, especially India, or the south
and east Mediterranean areas.22,24–26
No standardized susceptibility assays for Giardia iso-
lates are available,27 and susceptibility testing in the
laboratory is challenging due to genomic complexity of
the parasite. Moreover, isolates are difficult to culture, and
growth rates may differ between isolates and assemblages.
The microaerophilic environment in which Giardia thrives
is difficult to mimic in vitro for drug susceptibility assays.
Experiments may be performed in unfavorable high levels
of O2, affecting growth rates and MTZ metabolism of
Giardia. Thus, a reliable evaluation of MTZ’s activation
and tolerance can be difficult to obtain.28 Studies of MTZ
metabolism pathway genes in Giardia are mostly based on
gene expression analysis in isogenic laboratory-derived
resistant Giardia of the assemblage AI strains, rarely
found in humans.13,18,29–34 So far, no specific markers
for resistance in Giardia have been discovered, and resis-
tance is likely complex and based on several factors. These
factors could include amino acid variations in proteins and
altered function, post- or pre-translational variants,
changes in expression of activating or protective proteins,
modifications of regulatory pathways and epigenetic
modifications,16,35–39 and a recent study of resistant
Giardia strains showed that MTZ is capable of inducing
significant changes in proteins found in the antioxidant,
electron transport, and pyruvate catabolism networks. In
addition, a correlation between acetylation of these pro-
teins and MTZ resistance was found.35
Begaydarova et al 2015 investigated clinical isolates
and linked PFOR gene expression to MTZ resistance, but
PFOR was not found to be a good resistance marker.40
Another study by Galeh et al 201641 linked non-
synonymous single nucleotide variants (nsSNVs) in
PFOR and NR genes to MTZ resistance and possibly
through reduced translation and thereby reduced MTZ
activation. Genetic variation in Giardia genome is not
well known, except for a few genotyping genes, ie, triose
phosphate isomerase (tpi), glutamate dehydrogenase (gdh)
and beta-giardin (bg).42 The genetic variation among
Giardia isolates has in one study been found to be low
for some assemblage A genes, ie, Fd3 (DHA2_154390)
with more SNPs in assemblage B.43 However, the back-
ground genetic variability of the parasites’ MTZ metabo-
lizing pathways and management of the oxidative and
nitrosative stress has not been investigated in detail and
constitutes an important basis for further research into
potential markers of MTZ resistance.
Laboratory-induced MTZ resistance may be lost during
one en/excystation cycle,44 indicating that metabolic
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adaptations are likely to contribute to resistance. Still, the
recent emergence of rapidly increasing clinical MTZ resis-
tance raises the suspicion that strains with a genetically
inheritable trait for resistance are now circulating. Indeed,
one laboratory-induced resistance line has been shown to
possess a non-sense mutation in one of its NR-1 alleles.16
However, this challenge may best be studied by examining
current clinical isolates rather than laboratory strains
obtained decades ago. The prospect for whole genome
sequencing of purified cysts from clinical stool samples
makes it possible to perform such studies.45 The aim of
our study was to investigate the general genetic variation
in proteins involved in metabolic pathways associated with




A PubMed literature search was performed using the
word Giardia in combinations with one or two of the
words: MTZ, refractory, resistance and oxidative stress,
to identify genes in the MTZ metabolism pathway and
oxidative and nitrosative stress management in Giardia.
The search aimed to identify genes that were upregulated
or downregulated during exposure to MTZ and/or free
radicals or associated with the activation or inactivation
of MTZ and genes with antioxidant properties. These
publications and their references were used to establish
a list of 29 candidate genes (see Table 1). In order to
identify pairwise shared genes and the correct gene ID
for Giardia assemblage A2 and B, supplementary data
from Adam et al was used.46 Finally, the Giardia DB
(http://giardiadb.org) was used to find gene orthologs and
paralogs. For the NR genes analyzed in this study, the
annotations NR-1 and NR-2 have been used for clarity.
NR-2 is also known as GlNR1/Fd-NR2 (gene ID:
Gl50803_22677), and NR-1 as GlNR2/Fd-NR1 (gene
ID: Gl50803_6175). For the two genes PFOR-1 and 2,
the literature annotations were contradicting, and no more
specifications could be found in the Giardia DB. The
annotations used for the PFORs in this study are accord-
ing to GenBank. The annotations of Fds used in our
study is based on Müller et al 2008 and Ansell et al
2017.16,47 One hypothetical Fd presented by Nixon et al
200248 and Ansell et al 2017,16 Fd5, could not be found
in the reference genomes of A2 and B, nor by GenBank
blast. Another hypothetical Fd (DHA2_153401 and
GSB_151614) was named Fd6 in tables and figures.
Some of the putative Fds presented in this study may
actually be domains in a larger protein but are presented
as single Fds until more is known.
Giardia isolates
Twelve isolates of Giardia assemblage A2 and eight
isolates of assemblage B were cultured from human
clinical stool samples between 2011 and 2015 at the
Robert Koch Institute, Berlin, Germany. The stool sam-
ples were collected by the Institute of Tropical Medicine
and International Health, Charité, Berlin, Germany. One
of the isolates, P324, was obtained from the
Tropenmedizinische Ambulanz, University hospital
Düsseldorf, Germany. No clinical data for the samples
have been collected. Giardia cysts from the stool sam-
ples were purified using a two-step sucrose gradient
centrifugation. The cysts were excysted using a standard
two-step excystation method,49 in order to acquire tro-
phozoites. The trophozoites were grown in Diamond’s
TY-S-33 medium supplemented with bile at 37°C
according to.50 Collection of the trophozoites was done
from confluent cultures in 11 mL tubes, and then the
DNA was extracted using Maxwell® 16 FFPE Plus LEV
DNA Purification Kit (Promega BioTech AB, Sweden,
cat AS1135) together with Maxwell® 16 instrument
(AS1000). The quality and amount of DNA was vali-
dated with NanoDrop and the concentration of the DNA
was verified with Qubit 2.0 (Life Technologies, Grand
Island, NY).
Genome sequencing
Fragmented Giardia DNA (2 μg, 550 bp insert size) from
the trophozoites was first prepared and indexed using
Illumina TruSeq DNA PCR-Free Sample Prep Kit (Cat.
Nr 20015962 and 20015960S). Library size distribution
was validated using the Agilent Technologies 2100
BioAnalyzer, High Sensitivity DNA chip, and quantifica-
tion was done using the KAPA Library Quantification Kit
for Illumina sequencing platforms. Normalized whole gen-
ome Giardia DNA-libraries were sequenced using the
Illumina MiSeq paired-end technology (2×300 bp).
FASTQ-files from the sequencing were assembled and
aligned to the corresponding reference genomes of
Giardia assemblage A2 and B (v.26) using Bowtie
2-2.2.3.51 The reference genomes were obtained from
Giardia DB in January 2016 versions 2013-11-25.52
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Variant analysis
Aligned data were analyzed using Geneious v.10.2.4.
Variant calling was done to identify SNVs using the
parameters minimum variant frequency 0.1 and
a minimum coverage of 10 nucleotides. The coding
regions (CDS) of 29 candidate genes (including pre,
150 bp, - and post-coding regions, 50 bp) were extracted
from Giardia assemblage A2 and B in Geneious. For
genes with introns (Fd3 in both assemblages), genetic
analysis was done in the CDS and SNVs in introns are
therefore not presented. To obtain all the SNVs in one
alignment, the 29 genes from each isolate were concate-
nated, and then compared against each other assemblage-
wise. Comparisons of the 29 genes were also performed
in Geneious using a global alignment with free end gaps.
Alignments of ferredoxin domains are based on findings
from Nixon et al 2002,48 and for more detailed informa-
tion see the Supplementary material. For each gene, the
total number of possible SNV positions has been used.
The SNVs were divided into nsSNVs or synonymous
SNVs (sSNVs) in the coding regions or as SNVs in the
non-coding regions. Ratios for sSNV and nsSNVs were
calculated for each gene.
Homology modeling of the
nitroreductases and ferredoxins
Homology modeling of the NRs and ferredoxins 1–6 were
done based on the amino acid sequences used in the gene
analysis. Models were created using Protein Homology/
analogY Recognition Engine V 2.0 (Phyre2) server with
intensive mode.53 Models were visualized and superim-
posed in PyMol (The PyMOL Molecular Graphics System,
Version 2.1.0 Schrödinger, LLC).
Storage of data
All genetic data is kept on a secure server; Norwegian
e-infrastructure for Life Sciences.
Results
Whole genome sequencing of 20 cultured Giardia assem-
blage A2 and B isolates was successfully carried out with
an average coverage of 31.1 (110.3) (see Table S1) for the
29 genes of interest. Flavohemoprotein (DHA2_154000
and GSB_151570), was found to have a substantially
higher coverage (87.6 (54.2)), where a total of 17 of the
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Based on the criteria in the literature search, 29 candi-
date genes were selected and are presented in Table 1.
For the 29 candidate genes, the genetic variation was
analyzed across the 12 assemblage A2 and eight assem-
blage B clinical isolates. The average number of nsSNVs
per gene length was 0.3 % for assemblage A2 and 1.2%
for assemblage B. Averages for SNVs for each gene are
presented in Table S2. One of the genes in this study,
Fd3, was found to have a 35 bp intron in assemblage A2
and a 36 bp intron in assemblage B, which supports
earlier findings.43,54
Genes involved in the MTZ and oxidative
stress and nitrosative stress management
Considerably more nsSNVs could be found in the
Giardia assemblage B isolates than in the assemblage
A2 isolates. A color-graded heatmap of the nsSNVs
causing amino acid changes in the 29 proteins involved
in MTZ metabolism, oxidative and nitrosative stress
management is therefore only shown for Giardia assem-
blage B (Figure 1). The genetic variation in the flavo-
hemoprotein (GSB_151570) is not illustrated in Figure 1
due to high frequency of SNVs and variably higher
coverage than the average.
For two of the genes with highest frequency of
genetic variability in assemblage B (GSB_151294 -
thioredoxin peroxidase and GSB_153178 – NR-1), the
nsSNVs constituted over 4% of the nucleotides in the
gene, and only two genes were found to be without any
nsSNVs (histone H2A; GSB_151412 and Fd6;
GSB_151614). The average percentage of any SNV
per CDS length was 5.4% in Giardia assemblage
B and 1.1% in assemblage A2.
The majority of the genes was shown to have at least
one sSNV, except for the four genes Fd3; DHA2_154390,
NR-1; DHA2_153380, Fd1; DHA2_9662 and NADPH
oxidoreductase putative; DHA2_17151 in assemblage
A2. sSNVs were present in all genes in assemblage
B. SNVs in the pre-CDS regions were shown to be higher
in assemblage B (average of 10.1 SNVs in 150 bp) than in
assemblage A2, where the average was found to be 1.1
SNVs per 150 bps. Post-CDS regions had generally lower
variability (0.3 in A2 and 4.2 in B for 50 bp).
Nitroreductases
Three different NRs were investigated for the presence
of SNVs in this study, the NR-1, NR-2 and the oxygen-
insensitive NTR-1. NR-1, had one of the highest
numbers of nsSNVs (4.1%) for Giardia assemblage B,
with more nsSNVs than sSNVs in the CDS. However,
there were lower than average numbers of SNVs in the
non-coding regions of the NR-1 in assemblage B. The
NR-1 gene in assemblage A2 was found to be fully
conserved without any SNVs in the coding or non-
coding regions. The NR-2 gene sequence also had high
numbers of nsSNVs in Giardia assemblage B (2.1%),
and SNVs in the pre-CDS regions were higher than the
average (21 vs 10.1 out of 150 bp). The NR-2 in
Giardia assemblage A2 had low numbers of SNVs,
where only one was a nsSNV. The NTR-1 gene was
fully conserved in assemblage A2, and had lower than
average numbers on non-syn SNVs in B.
Ferredoxins
The Fds are proposed to be co-factors for the MTZ
activating proteins, PFOR-1 and 2, and changes in
these co-factors could potentially affect their function,
binding and role. We found that three of the ferredoxins
in the Giardia assemblage B isolates, Fd2; GSB_10329,
Fd4; GSB_153527 and Fd1; GSB_9662, had higher
numbers of nsSNVs than the average of 1.2% (respec-
tively 3.1%, 1.7% and 1.7%). Interestingly the Fd2 was
one of the proteins with the most SNVs in the post- and
pre-CDS regions of all the genes investigated in assem-
blage B, and it also had a high number of nsSNVs in the
coding region.
For Giardia assemblage A2 two of the ferredoxins had
higher numbers of nsSNVs than the average of 0.3%,
respectively Fd2; DHA2_10329 (2.1%) and Fd6;
DHA2_153401 (1.1%). One fascinating finding was that
the Fd6 was fully conserved in Giardia assemblage
B while assemblage A2 had some SNVs present.
Antioxidant and metabolic proteins
Two of the free radical protective enzymes, prx
(GSB_151294) and NADH oxidase (GSB_9719) and
the metabolic protein alcohol dehydrogenase
(GSB_13350) was demonstrated to have higher numbers
of nsSNVs in assemblage B than the average. Post-CDS
analysis revealed that TrxR; GSB_9827 was one of the
proteins with the highest number of SNVs, while
NADPH oxidoreductase putative; GSB_17150, the two
prxs, GSB_153801 and GSB_14521, malate dehydro-
genase; GSB_3331, flavoprotein; GSB_10358 and alco-
hol dehydrogenase; GSB_13350, all had higher numbers
of post-CDS SNVs than the average.
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Alignment of the ferredoxins and the nitroreductases
Some of the ferredoxins and NRs were found to have high
numbers of nsSNVs in many of the Giardia assemblage
A and B isolates. The amino acid changing SNVs and their
positions in the proteins were therefore analyzed further, and
an alignment was made to compare the cysteine domains in
the five different ferredoxin proteins included in this analysis
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Figure 1 Heat map of proteins in the metabolism of metronidazole and oxidative/nitrosative stress management in Giardia assemblage B. Metronidazole (MTZ) passively
diffuses through the trophozoite membrane and needs to be activated into toxic intermediates to execute its function as an antibiotic. Several theoretical intermediates exist
for MTZ. MTZ can be activated either through the enzymes pyruvate: ferredoxin oxidoreductase (PFOR)-1 and/or 2 with ferredoxin (fd) as a co-factor, by nitroreductase-1
with flavin mononucleotide (FMN) as a co-factor or by thioredoxin reductase with the redox cofactor flavin adenine dinucleotide (FAD). MTZ may also be converted into an
inert metabolite through the enzyme nitroreductase-2. The MTZ-NO formed during activation may react with O2
− and create the reactive free radical molecule
peroxynitrite (ONOO−). In order to remove toxic free radicals many enzymes exhibit protective functions, ie, thioredoxin peroxidase enzymes may convert the
peroxynitrite to the harmless molecule nitrate (NO3
−). The free radical form of NO· may be converted to nitrate by flavohemoprotein (O2 dependent reaction). In the
microaerophilic environment, Giardia is repeatedly exposed to the harmful O2/O2
−. The O2 may be metabolized to H2O2 through desulfoferredoxin (SOR) and further H2O2
is converted to H2O by the thioredoxin peroxidase enzymes. O2 may also be converted to H2O by NADH oxidase enzymes or the O2 scavenging enzyme flavoprotein.
Other enzymes may cause free radicals in Giardia, ie, NADPH oxidoreductase putative is areactive oxygen species (ROS) contributor due to conversion of O2 to a more
reactive free radical form (O2
−). Another contributor to ROS is the reduced version of thioredoxin and it may initiate protein misfolding. The color gradation of the proteins
represents the number of nsSNVs positions per length of each gene. *Thioredoxin reductase is active in both MTZ metabolism and reduction of the protein thioredoxin.
**Flavohemoprotein is a suspected multicopy gene and the number of SNVs has not been defined and is not represented by color in the heatmap.
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previously described in WB (Fd5)48 The proteins NR1, Fd1,
and Fd3 in assemblage A2 and Fd3 and Fd6 in assemblage
B had no nsSNVs in their ferredoxin domains. The nsSNVs
positioned around the cysteine residues in the ferredoxin
domains responsible for forming the Fe-S clusters binding
sites (electron transport sites) are shown in Figure 2.
Homology modeling of the ferredoxin
domains
In order to be able to analyze the effect of the amino acid
changes, homology modeling was used. The ferredoxin
domain sequence alignment presented in Figure 2 and
the putative cysteine residues for binding Fe-S clusters
are coded with the same color codes as shown in the
homology models of the domains in Figure 3. Homology
modeling indicates various differences within the ferre-
doxin domains.
Fd1, Fd2 and Fd4 can be superimposed on ferredoxin
domains of NR-1 and 2. All of them clearly have two
cysteine motifs, with four cysteines each, able to bind
Fe-S clusters, probably of the type 4Fe-4S.55,56 The rest
of the ferredoxins differ from the others by shape and
ability to bind Fe-S clusters. The Fd6 has two cysteine
motifs but one of the motifs only has three coordinating
cysteines instead of four, which could indicate that the
Fd6 only can bind one 4Fe-4S cluster or potentially one
4Fe-4S and an additional 3Fe-4S cluster (bound to
3-cystein motif). The Fd3 has only one clear motif for
binding 4Fe-4S cluster and in addition it has a proposed
elongated C-terminus. Fd5 has both an elongated N- and
a C-terminus.
Some of the amino acid substitutions were positioned
close to the ferredoxin domain with Fe-S cluster binding
cysteines and sufficiently different in charge or hydro-
phobicity to be able to potentially cause a change sig-
nificant enough to affect protein function. Some of the
amino acids in the ferredoxin domains are surface
exposed and changes here could potentially affect the
proteins’ ability to interact with other proteins in possi-
ble intermolecular electron transfers. These changes
include changes from a positively charged amino acid
such as K to a negatively charged E or D seen in NR-1
assemblage B, or a change from E to K in Fd2 assem-
blage A2 and in Fd2 from assemblage B where G is
changed to R.
Figure 2 Alignment of the ferredoxins (Fd1-Fd6) and nitroreductase 1 and 2. The genetic variability is represented by alternative amino acids under the original protein
sequences. Ferredoxin 5 was found to be an uncharacterized protein and is not annotated in the DHA2 and GSB genomes and is thus presented by the hypothetical
sequence from Giardia WB. Only the ferredoxin domains in the N-terminus of the proteins are represented, and the nitro-flavin mononucleotide (FMN) reductase domain in
the C-terminus of the NRs are not shown. The cysteine residues responsible for forming the iron-sulfur clusters are shaded in either black or magenta to represent how the
residues connect. *end of the protein, +the protein has been cut and only the ferredoxin domain is shown.
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InNR-1 fromassemblageB, S can be changed to P (pos. 70
Figure 2), and in NR-2 from A2, P can change to S (pos. 41 in
Figure 2) which might change the conformation of the protein
backbone, as P is structurally more rigid than other amino
acids. These SNVs are located next to or between two
cysteines coordinating Fe-S cluster binding in NR-1 and
NR-2, respectively. SNVs that could potentially have an effect





























I / V G / E
A / V
A / V
Figure 3 Cartoon tube representation of homology models of Nitroreductase (NR) ferredoxin domains and ferredoxins (Fd) 1–6. Cysteine residues responsible for the
binding of [Fe4-S4] iron–sulfur cluster are represented with sticks colored with dark gray and red for clusters 1 and 2, respectively. For the mutations caused by SNVs, the
original amino acid residue is shown in stick and possible mutations are marked with one letter code. (A) NR1_A2 (grey), NR2_A2 (cyan), NR1_B (yellow) and NR2_B
(brown) (B) Fd1_A2 (grey), Fd2_A2 (cyan), Fd1_B (yellow) and Fd2_B (brown) (C) Fd3_A2 (grey), Fd3_B (cyan). The extended C-terminus has been truncated from the
figure and is marked with an asterisk. (D) Fd4_A2 (grey), Fd4_B (cyan). (E) Fd5_WB (grey) (F) Fd6_A2 (grey), Fd6_B (cyan).
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change inNR-2 from assemblageBandG toE (pos 38) change
in Fd4 from assemblage B.
Discussion
The genome of Giardia trophozoites is tetraploid, consisting
of two diploid nuclei. The variability among and within the
assemblages can therefore potentially be high. In our study
we show that the nsSNVs are common in the investigated
genes in culturable clinical isolates of Giardia assemblage
A2 and B. Generally, Giardia assemblage B had higher
numbers of SNVs in the 29 genes investigated, and relates
well to the earlier finding that the allelic sequence hetero-
zygosity (ASH) in assemblage B is up to 0.53%,57 whereas
the ASH of two A2 isolates, AS-98 and AS-175, has been
determined to be 0.25–0.35%.46 In Giardia assemblage B,
particularly high numbers of nsSNVs were found in gene
sequences encoding MTZ activating enzyme NR-1, the
PFOR co-factors Fd2, Fd1 and Fd4, the protective enzymes
prx and NADH oxidase, the metabolic enzyme alcohol
dehydrogenase, in addition to the MTZ inactivating enzyme
NR-2. In assemblage A2, gene sequences of Fd2, Fd6 and
the ROS-contributing enzyme NADPH oxidoreductase
putative had the greatest number of nsSNVs.
Homology modeling shows that some of the amino
acid changing SNVs are in close proximity to the cysteine
residues responsible for forming Fe-S clusters and could
potentially affect binding affinities of the proteins NR-1,
NR-2, Fd2 and Fd4, or how they may exert their roles as
electron transferring proteins.
Genetic variation as potential resistance
markers
High numbers of nsSNVs found in the Giardia assemblage
B isolates may indicate that assemblage B mutates faster
than assemblage A2 isolates. The higher variation frequen-
cies found in the B isolates may be associated with greater
functional variation, higher prevalence of disease in
humans and higher rates of treatment-refractory cases.58,59
A recent study,41 using clinical Giardia isolates, sug-
gested that nsSNVs in NR-2 and PFOR genes could be
linked to resistant Giardia isolates, but the study was
based on only two treatment-refractory isolates. In addi-
tion, this study gives potential evidence that different
haplotypes of these two genes may exist within the gen-
ome. This finding correlates with our observation that the
numbers of nsSNVs in the NR-2 protein in Giardia assem-
blage B was higher than average. The PFORs in our study
were found to have lower numbers of nsSNVs than aver-
age. However, the co-factors for the PFORs, Fds, were
found to be highly variable within three of the five Fds in
assemblage B and two of the Fds in Giardia assem-
blage A2.
The role of the MTZ activating enzyme, PFOR, is
thought to be the transfer of electrons, through its bound
Fe-S clusters, to soluble Fds.38 Lower levels of PFOR and
ferredoxin enzyme activities have been characterized in
resistant Giardia cultures and were also connected to
MTZ sensitivity in clinical isolates.16,32,60,61 PFOR gene
expression was, however, not found to be of significant
difference in patient isolates with different susceptibility to
MTZ in vitro.40
In other anaerobe organisms, genetic markers of resis-
tance have been identified. The enzyme known as oxygen-
insensitive nitroreductase, has been shown to be an MTZ
activating enzyme in Helicobacter pylori and Escherichia
coli, and bacteria with inactivated NTR or nsSNVs in this
gene, may be resistant.62–64 Additionally, resistance in the
parasite Trichomonas vaginalis has been associated to
SNVs in the two nitroreductase genes ntr4Tv and
ntr6Tv.65 SNVs found in intergenic regions of 13 genes
in T. vaginalis have been linked to resistance as well, and
the study suggests that a panel of genetic markers could be
used as a diagnostic tool of resistance.66 Intergenic analy-
sis should be done in Giardia as well, in order to predict
whether SNVs here may play a role in MTZ resistance.
An enzyme in Giardia known as oxygen-insensitive
nitroreductase (NTR-1), is similar to the NTR in bacteria,
and it might have been acquired through lateral transfer
from bacteria.48 The NTR-1 is different from the NR-1 and
NR-2 due to missing ferredoxin domains in the protein and
may not play a key role in the Fe-S cluster electron
transportation. We found the presence of nsSNVs in
NTR-1 to be low in our analysis. Whether this enzyme
has a role in MTZ activation in Giardia is not known, but
it may have a fundamental role in protection against oxi-
dative- and nitrosative stress, as it is O2 insensitive, and
has been shown to be upregulated during MTZ exposure.15
Giardia could also potentially down-regulate enzymes
that detoxify oxygen to protect itself from the activated
form of MTZ. This down-regulation is favorable due to the
fact that MTZ may only be reduced in microaerophilic or
anaerobic environments. Presence of oxygen helps to
deactivate MTZ by futile cycling, creating ROS.60 The
ROS will then require extensive detoxification by enzymes
in the antioxidant system to avoid harmful cell damage.67
Saghaug et al Dovepress
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In Giardia assemblage B, high variability was found in the
two oxygen detoxifying proteins NADH oxidase
(GSB_9719) while the ROS contributing enzyme
NADPH oxidoreductase putative (GSB_17150) was
found to have higher variability than the average for both
assemblages. Oxidoreductases have previously been
shown to be upregulated when Giardia is challenged with
H2O2.
37 The functions and characteristics of the NADPH
oxidoreductases and their potential paralogs should be
investigated in future studies, to understand whether they
have a role MTZ resistance, as oxidoreductases with null
mutations, causing non-functional proteins, have been
associated with MTZ resistance in H. pylori.68
Some of the genes investigated in the present study
were found to have few, or non-existent, nsSNVs (Fd6 and
Histone H2A in assemblage B, in addition to 10 genes in
assemblage A2, see Table S2). Changes in these conserved
genes could potentially have more serious consequences
and affect biological functions such as survival in culture,
clinical infectivity and tolerance to free radicals, and could
be something to address in future studies of culturable and
non-culturable isolates.
Resistance induced in the laboratory may have differ-
ent manifestations than clinical resistance, and the use of
Giardia isolates directly from patients, without undergoing
laboratory culturing are likely to supplement studies with
isogenic laboratory strains.69,70
Non-coding regions
SNVs found in non-CDS regions of genes could affect
regulatory elements and promoters which may further
potentially affect gene transcription, mRNA translation
and next protein expression.35,71 The genes, NR-1 and
the PFOR co-factor Fd2, were found to have especially
high numbers of pre-CDS SNVs in Giardia assemblage
B in our study. The sequence preceding the CDS, harbor
transcription promoters, and based on scarce knowledge of
these in Giardia, they are short, around 50 bp long, initia-
tor-like AT-rich sequences approximately −65 to −29 base
pairs upstream the ATG start codon.57,72 Low conservation
of the promoters in Giardia has previously been reported
to be common, and may be related to our findings.72 How
the presence of SNVs in the promoter regions of genes in
Giardia may affect transcription of the genes is however
not known yet. The interpretation of the SNV findings in
these regions are therefore limited, and in this study, we
decided to present them, but not to evaluate their potential
regulatory roles.
Ferredoxin domains and SNVs
The alignment of the NRs and Fds in this study, only include
the ferredoxin domains, responsible for binding the Fe-S
clusters (see Figure 2). This region has earlier been asso-
ciated with drug activation, as the electrons are thought to be
transferred from the ferredoxin domain to the active reduc-
tion center in order to reduce MTZ.18 The active reducing
center in the NRs has earlier been characterized as a nitro-
flavin mononucleotide (FMN) reductase domain.18
Most of the nsSNVs present in the ferredoxin domain
alignment in Figure 2 will probably not alter the function
of the proteins as the changes do not alter the basic proper-
ties, eg, polarity or charge, of the amino acid residues.
Some other changes are located close to the cysteine
part of the 4Fe-4S binding motif and might, therefore,
affect the geometry or the electron transfer properties of
the Fe-S cluster. Activated MTZ has previously been
speculated to be able to react with nucleotides and
cysteines (free thiol groups) and form adducts.38 Whether
MTZ can form adducts with the proteins investigated in
the present study and whether amino acid substitutions
close to the cysteine domains could affect formation
must be investigated further using structural- and molecu-
lar biology studies.
Other proteins that also have distinct Fd domains
include the two large proteins PFOR-1 and PFOR-2.
They have been hypothesized to have three motifs to
bind 4FeS4 cluster. Even if the PFORs have their own
Fd domains, they are still thought to use Fds in the cytosol
for electron transfer and MTZ activation.38
Coverage and multicopy genes
Several of the genes in this study were found to have
paralogs annotated in the genomes of Giardia assem-
blage A2 and B, and we aimed to include genes present
in both of the Giardia assemblages. A total of 12 para-
logs were found for the NADPH oxidoreductase, and an
alignment was done to compare their similarity (data not
shown). The alignment showed they were only 78.3%
similar to one another, and probably not multicopy
genes.
We were not able to investigate the true number of
sSNVs and nsSNVs of the gene sequence of flavohemopro-
tein due to its variable higher coverage than the other genes,
indicating that it is present in a variable number of copies in
different isolates (Table S1). The SNVs could possibly be
a combination of SNVs of all the alleles present of the
flavohemoprotein gene and not true SNVs of one gene.
Dovepress Saghaug et al
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Two shorter paralogs of flavohemoprotein,
DHA2_153759 and DHA2_152971 were identified, and
had high identity to the longer flavohemoprotein
DHA2_154000 (data not shown). Functions of these two
proteins should be investigated in detail in the future to
know if they have similar properties as the
DHA2_154000, or if they potentially could be wrongly
annotated or fragmented versions of DHA2_154000. The
shorter flavohemoproteins could have affected the cover-
age of the Giardia assemblage A2 isolates, as they each
would align to the 5ʹ or 3ʹ end of the DHA2_154000 gene.
They do not overlap, leaving approx. 500 bp in the middle
of the gene. The coverage was nevertheless even, and the
two paralogs in assemblage A2 would also not explain the
higher coverage of the assemblage B gene GSB_151570.
The potential copy-number variation in this gene, coupled
with amino acid changing SNVs could be important for
understanding Giardia’s capability of handling oxidative
stress, as flavohemoprotein is an important NO and O2
scavenging enzyme.16,20,36,37,73–76
We also noted that histone H2A had 24 times lower
coverage than the average in one of the assemblage A2
isolates. Possibly this gene could be missing, or found in
another contig in this isolate, or a sequencing error may
have occurred.
WGS limitations
The Illumina MiSeq paired-end technology sequencing
used in our study gave a low coverage for several of the
isolates and their genes, limiting the SNV analysis. For
two assemblage B and one assemblage, A2 isolates the
average coverage for the genes was only 11.3–14.0
(Table S1). Low coverage decreases the possibility of
finding low prevalence SNVs, as the cutoff value was set
to >10 in coverage. In addition, short reads of 2×300 bp
prevented identification of full-length gene haplotypes in
our study. The relatively crude reference genomes used in
this analysis can also potentially hamper the SNVanalysis,
as the Giardia isolates used for obtaining the reference
genomes have been grown in culture for decades and still
consist of several hundred contigs, instead of the predicted
five chromosomes.
Conclusion
Genetic variation in the form of SNVs is common in both
of the human-infecting Giardia assemblages A2 and
B. Assemblage B showed higher variation than assem-
blage A2, and presence of amino acid changing SNVs
were especially high in genes associated with MTZ meta-
bolism (ferredoxins, nitroreductase-1 and 2) and for some
of the genes important in the detoxification of free radicals
(thioredoxin peroxidase and NADH oxidase). Some of the
discovered SNVs in this study could potentially affect the
electron transfer properties of Fe-S clusters in some of the
NRs and Fds investigated. Further studies are needed to
address their functional properties, but study design can be
guided by the presented findings. Analysis of genetic
variation in circulating MTZ susceptible and treatment-
refractory clinical Giardia isolates will be important to
address the recent increase in MTZ resistant Giardia
cases. The present study can be regarded as a basis for
further studies into how genes in the metabolizing path-
ways may differ between resistant and susceptible Giardia
isolates.
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